The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-16. Anything still debated is marked as such rather than presented as settled.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== Early life and career == Brandt was born into a Jewish family in Newark, New Jersey, where his parents, Irving and Esther Brandt, owned a candy shop. He graduated from Rutgers University in 1971. Brandt then obtained his medical degree from Hahnemann Medical College and completed an internal medicine residency at New York University, followed by a dermatology residency at the University of Miami. He set up a practice in Miami in 1982, and subsequently opened up a practice in New York City in 1998.
CYP2D6 for which it is both a substrate and a potent inhibitor. CYP2B6 (strong) inhibitor. CYP3A4 (weak) inhibitor. CYP1A2 (weak) inhibitor. CYP2C9 (weak) inhibitor. CYP2C19 (weak) inhibitor. Paroxetine has been shown to be an inhibitor of G protein-coupled receptor kinase 2 (GRK2).
=== Mechanism of action === As an adenosine nucleoside triphosphate analog (GS-443902), the active metabolite of remdesivir interferes with the action of viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN), causing a decrease in viral RNA production. In some viruses, such as the respiratory syncytial virus, it causes the RNA-dependent RNA polymerases to pause, but its predominant effect (as in Ebola) is to induce an irreversible chain termination. Unlike with many other chain terminators, this is not mediated by preventing addition of the immediately subsequent nucleotide, but is instead delayed, occurring after five additional bases have been added to the growing RNA chain. For the RNA-dependent RNA polymerases of MERS-CoV, SARS-CoV-1, and SARS-CoV-2, arrest of RNA synthesis occurs after incorporation of three additional nucleotides. Hence, remdesivir is classified as a direct-acting antiviral agent that works as a delayed chain terminator.
Sources: en.wikipedia.org
The cephalopod radula consists of multiple symmetrical rows of up to nine teeth – thirteen in fossil classes. The organ is reduced or even vestigial in certain octopus species and is absent in Spirula. The teeth may be homodont (i.e. similar in form across a row), heterodont (otherwise), or ctenodont (comb-like). Their height, width and number of cusps is variable between species. The pattern of teeth repeats, but each row may not be identical to the last; in the octopus, for instance, the sequence repeats every five rows. Cephalopod radulae are known from fossil deposits dating back to the Ordovician. They are usually preserved within the cephalopod's body chamber, commonly in conjunction with the mandibles; but this need not always be the case; many radulae are preserved in a range of settings in the Mason Creek. Radulae are usually difficult to detect, even when they are preserved in fossils, as the rock must weather and crack in exactly the right fashion to expose them; for instance, radulae have only been found in nine of the 43 ammonite genera, and they are rarer still in non-ammonoid forms: only three pre-Mesozoic species possess one.
The 1982 biopic film Frances depicts actress Frances Farmer (the subject of the film) undergoing transorbital lobotomy (though the idea that a lobotomy was performed on Farmer, and that Freeman performed it, has been criticized as having little or no factual foundation). Katherine Dunn's 1989 novel Geek Love centers on a freak show whose leader founds a cult practicing amputation and lobotomy. Joyce Carol Oates's 1995 novel Zombie includes a verbatim extract of Freeman and Watts's 1942 treatise Psychosurgery describing leucotomy. The antihero Quentin reads this passage and similar descriptions of lobotomy. Sexually fantasizing about submissive lobotomized patients, Quentin seeks seeks to replicate Freeman's transorbital lobotomy technique on his victims using an icepick. Jeffrey Dahmer was Oates's inspiration for the character of Quentin; Dahmer did not use Freeman's technique on his victims, but rather drilled into their skulls to pour acid into them.
=== Retrospective === Retrospective reviews have typically been more appreciative. Craig Butler of AllMovie wrote that "Stone Cold might seem like a throwaway action film built around a sports personality but it's actually much more. In fact, this is a model b-movie". Of the cast, he said that "Bosworth acquits himself well as the hero" and "Lance Henriksen is charming and chilling", while "William Forsythe delivers a feral, rip-snorting turn". He also pointed that "Craig Baxley does an excellent job in the director's chair." Svet Atanasoff of Blu-ray.com deemed that "Stone Cold might be the ultimate macho action film". Not convinced by Bosworth's contention that the excision of its family themes doomed the film, he claimed that he had "always liked it". Ian Jane of DVD Talk commented that "Stone Cold may be dumber than a bag of rocks, and Brian Bosworth might have all the acting charisma of a corn flake, but hot damn if this movie isn't a fantastic slice of brainless action moviemaking done right." John Higgins of Starburst called it "a no-brainer of an action film, following a traditional template and with sufficient bang, clever editing and brutal violence to just carry it over the finish line." Comparing it to Brandon Lee's equally neglected Rapid Fire, he concluded that "it may be short on plot and character, but it is a highly effective action thriller".
== Adverse effects == more than 1/10 of all patients hypokalaemia, which can lead to nausea, muscular weakness or cramps, and ECG abnormities 1/100 to 1/10 hyponatraemia, which can lead to headache, nausea, drowsiness or confusion orthostatic hypotension initially increase of urea, uric acid and creatinine, which can lead to a gout attack in predisposed patients 1/1000 to 1/10,000 allergic reactions of the skin hyperlipidaemia less than 1/10,000 haemorrhagic pancreatitis acute interstitial nephritis thrombocytopenia, leucopenia
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.